Core Viewpoint - Dyadic International, Inc. is set to report its financial results for Q3 2024 and will host a corporate update conference call on November 12, 2024, highlighting its focus on large-scale protein manufacturing for vaccines and therapeutics [1]. Company Overview - Dyadic International, Inc. specializes in the efficient large-scale manufacture of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications such as food, nutrition, and wellness [4]. - The company utilizes the fungus Thermothelomyces heterothallica for its gene expression and protein production platforms, aiming to lower production costs and improve the performance of biologic vaccines and drugs [5]. Technology and Innovation - Dyadic's lead technology, the C1-cell protein production platform, is designed to enhance the development and production of biologic products at flexible commercial scales [5]. - The Dapibus™ platform enables rapid development and large-scale manufacture of low-cost proteins and other biologic products for non-pharmaceutical uses [5]. Strategic Goals - The company is committed to advancing its proprietary microbial platform technologies to support the development of effective preventative and therapeutic treatments globally [6]. - Dyadic aims to facilitate the faster market entry of vaccines and biologic products at greater volumes and lower costs [7].

JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient, large-scale manufacture of proteins for use in non-pharmaceutical applications including food, nutrition and wellness, as well as animal and human health therapeutics and vaccines, today provided an update on business progress and announced its attendance at the Bioprocess International Conference in Boston, September 2 ...

Dyadic International, Inc. (NASDAQ:DYAI) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President and CEO Joseph Hazelton - COO Patrick Lucy - Chairman Conference Call Participants John Vandermosten - Zacks Operator Good evening and welcome to the Dyadic International's Q2 2024 Conference Call. Currently, all participants are in a listen-only mode. Following the management's prepared remarks, there will be a brief question-and-answer sessio ...

Exhibit 99.1 Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress Alternative Proteins ● Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and Biologicals ● Entered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbumin ● Ongoing development of a robust pipeline of non-pharmaceutical recombinant product candidates ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC® DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) State or Other Jurisdict ...

JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in nonpharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, Augu ...

About Dyadic International, Inc. According to the terms of the agreement, Dyadic will receive an upfront milestone payment of $1.5MM and have agreed to a share of profits received by PHB from the sale of animal-free recombinant albumin products produced using Dyadic's filamentous fungal microbial platforms. A portion of the upfront milestone payment will be allocated to the technology transfer and commercialization effort. The initial focus of the partnership will be the commercialization of recombinant hum ...

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets. "Over the past few years, we have observed both increased interest and demand for alternative sources of protein for the diagnostic and life sciences industries. We are thrilled ...

JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced that its management will be attending the following industry events during June 2024. BIO 2024 San Diego Convention Center, San Diego, CA Jun 3 – 6, 202 ...

JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced that its management will be attending the following industry events during June 2024. BIO 2024 San Diego Convention Center, San Diego, CA Jun 3 – 6, 202 ...